Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
10/12/17
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
08/16/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/14/17SC 13GA statement of beneficial ownership of common stock by certain personsOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/02/1710-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
08/02/178-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
07/26/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
10/18/17Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia
PARSIPPANY, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration via nerve block for prolonged regional analgesia. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is April 6, 2018. ... 
Printer Friendly Version
09/27/17Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
PARSIPPANY, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chairman and chief executive officer, will testify this afternoon before President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis. The Commission, led by New Jersey Governor Chris Christie, was created to study ways to combat and treat drug abuse, addiction and the opioid crisis. The meeting, which will be held in Washington, D.C. today from ... 
Printer Friendly Version
09/26/17New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk
Patients receive an average of 85 pills following surgery; overprescribing leads to 3.3 billion unused postsurgical opioids every year An Analysis of the Impact of Opioid Overprescribing in America Middle-aged and Generation X women have highest rates of p... 
Printer Friendly Version
09/20/17Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
PARSIPPANY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Cantor Fitzgerald Global Healthcare Conference at 10:20 AM ET on Tuesday, September 26, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archiv... 
Printer Friendly Version
09/13/17Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent PARSIPPANY, N.J., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced a collaboration with Aetna, one of the nation’s leading diversified health care benefits companies, with the support of the American Association of Oral and Maxillofacial Surgeons (AAOMS), on a national program aimed at reducing the number of opioid tablets prescribe... 
Printer Friendly Version
09/06/17Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium
Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries PARSIPPANY, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that three poster presentations evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) administered as a regional nerve block to manage postsurgical pain will be presented at the New York School of Regional Anesthesia’s (NYSORA) 16th Annual Symp... 
Printer Friendly Version
09/05/17Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference
PARSIPPANY, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference at 10:50 AM ET on Monday, September 11, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will ... 
Printer Friendly Version
08/31/17Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wells Fargo Healthcare Conference at 8:15 AM ET on Thursday, September 7, 2017 in Boston, Massachusetts. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on t... 
Printer Friendly Version
08/09/17Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
PARSIPPANY, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wedbush Pacgrow Healthcare Conference at 9:10 AM ET on Tuesday, August 15, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Paci... 
Printer Friendly Version
08/02/17Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
-- EXPAREL® Net Product Sales Up 6% Year-Over-Year -- -- Full-year EXPAREL net product sales guidance of $290 to $310 million reiterated -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017. “We are pleased to report another quarter of solid EXPAREL growth and remain on track to deliver our full-year financial gui... 
Printer Friendly Version
>> Access Older Press Releases

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...